Gain Therapeutics, Inc. (GANX)
| Market Cap | 94.30M |
| Revenue (ttm) | 81,617 |
| Net Income (ttm) | n/a |
| Shares Out | 11.88M |
| EPS (ttm) | -1.35 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 53,986 |
| Open | 7.43 |
| Previous Close | 7.42 |
| Day's Range | 7.43 - 7.94 |
| 52-Week Range | 7.35 - 17.93 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | 30.00 (+277.8%) |
| Est. Earnings Date | Nov 11, 2021 |
About GANX
Gain Therapeutics, Inc., a development stage biotechnology company, develops various therapeutics to treat diseases caused by protein misfolding. It focuses on lysosomal storage disorders, such as rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover novel allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites and restore protein folding treating the underlying disease. It is developing structurally targeted allosteric r...
Financial Performance
In 2020, GANX's revenue was $28,881, a decrease of -30.07% compared to the previous year's $41,301. Losses were -$3.58 million, 63.1% more than in 2019.
Financial StatementsNews
Gain Therapeutics to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
- Conference Dates: September 20 th -23 rd -
Gain Therapeutics to Present at 2021 International Virtual GM1 Community Conference
BETHESDA, Md., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company focused on identifying and optimizing allosteric binding site...
Why Gain Therapeutics Shares Are Trading Higher Today
Gain Therapeutics Inc (NASDAQ: GANX) are trading higher Wednesday after the company announced positive topline data in a patient-derived iPSC study evaluating STAR compounds as a treatment for Gaucher a...
Gain Therapeutics' Gaucher, Parkinson's Candidate Shows Potential In Patient-Derived iPSC Study
The topline data from a study conducted at the University of Maryland School of Medicine (UMSOM) by Gain Therapeutics Inc (NASDAQ: GANX) evaluating two lead Structurally Targeted Allosteric Regulators (...
Gain Therapeutics, Inc. Announces Positive Topline Data in Patient-derived iPSC Study Evaluating STAR Compounds as a ...
GT-02287and GT-02329 compounds display positive effects on GCase activity and related parameters --- Study results demonstrate an increase in GCase protein levels with transport to the lysosomes and dec...
Gain Therapeutics, Inc. Announces Positive Topline Data in Patient-derived iPSC Study Evaluating STAR Compounds as a ...
GT-02287and GT-02329 compounds display positive effects on GCase activity and related parameters --- Study results demonstrate an increase in GCase protein levels with transport to the lysosomes and d...
Gain Therapeutics, Inc. to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
BETHESDA, Md., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company focused on identifying and optimizing allosteric binding site...
Gain Therapeutics, Inc. Reports Second Quarter 2021 Financial Results and Business Update
Announced Multi-Target Drug Discovery Collaboration with Zentalis Pharmaceuticals in Oncology --- Granted Two Patents for Compounds that Stabilize G-Case for Gaucher's Disease and other Synucleinopathie...
Gain Therapeutics to Present at the BTIG Virtual Biotechnology Conference
BETHESDA, Md., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”), a biotechnology company focused on redefining drug discovery by identifying and optimizing novel alloste...
Gain Therapeutics Announces Issuance of Two New PCT Patents Covering GBA and GALC Modulator Compounds for Treatment o...
Activity of GBA and GALC Enzymes Play Key Roles in the Neurodegenerative Diseases and Lysosomal Storage Diseases Activity of GBA and GALC Enzymes Play Key Roles in the Neurodegenerative Diseases and Lys...
Gain Therapeutics to Present at the Jefferies Virtual Healthcare Conference
BETHESDA, Md., May 27, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”), a biotechnology company focused on redefining drug discovery by identifying and optimizing allosteric bin...
Gain Therapeutics to Participate in Upcoming Virtual Investor Conferences in May
BETHESDA, Md., May 17, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”), a biotechnology company focused on redefining drug discovery by identifying and optimizing allosteric bin...
Gain Therapeutics, Inc. Reports First Quarter 2021 Financial Results
Completed successful initial public offering and raised $46 million in gross proceeds --- Appointed four new independent board of directors to strengthen leadership team --- Signed a multi-target collab...
Gain Therapeutics Presents Positive In Vitro & In Vivo Data on Its Orally Bioavailable Brain Penetrant Star Compounds...
Compounds reverse the neurodegenerative process observed in a Parkinson's disease in vivo model
Gain Therapeutics to Present at the B. Riley Securities' Virtual Neuroscience Conference
BETHESDA, Md., April 27, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ: GANX) (“Gain”) a biotechnology company focused on redefining drug discovery by identifying and optimizing allosteric bi...
Gain Therapeutics Announces Presentation at the International Association of Parkinsonism and Related Disorders 2021 ...
Abstract highlighting Gain's STAR candidate for Parkinson's disease selected as one of the 10 Best Abstracts at the conference Abstract highlighting Gain's STAR candidate for Parkinson's disease selecte...
Gain Therapeutics Announces Multi-Target Drug Discovery Collaboration Agreement with Zentalis Pharmaceuticals
Collaboration to use Gain's proprietary Site-Directed Enzyme Enhancement Therapy (SEE-Tx™) computational platform technology to identify new and previously difficult-to-drug oncology targets
Gain Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Overallotment Optio...
BETHESDA, Md., March 25, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (“Gain”) today announced the closing of its initial public offering of 3,636,364 shares of its common stock and full exercise of...
The IPO Market Had A Busy Week
Last week was a busy one for the IPO market with 11 IPOs raising $3 billion, joined by 24 SPACs that brought another $8.4 billion to the table. Chinese IoT platform developer Tuya Inc (NYSE: TUYA) raise...
Gain Therapeutics Announces Pricing of Initial Public Offering of Common Stock
Gain Therapeutics, Inc. (“Gain”) today announced the pricing of its initial public offering of...
Gain Therapeutics Files Registration Statement with SEC for Proposed Initial Public Offering
Gain Therapeutics, Inc. (“Gain”) today announced that it has launched the roadshow for its initial...
Lysosomal storage disorder biotech Gain Therapeutics files for a $40 million IPO
Gain Therapeutics, a preclinical biotech developing small molecule therapies for lysosomal storage disorders, filed on Friday with the SEC to raise up to $40 million in an initial public offering.
Gain Therapeutics IPO Registration Document (S-1)
Gain Therapeutics, Inc. has filed to go public with an IPO on the NASDAQ.